

# Index

## A

- Acute kidney injury (AKI)
  - animal models, 112
  - causes, 112
  - immune cell roles, 112–113
  - inflammation and neuroimmune interactions
    - cholinergic anti-inflammatory pathway
      - macrophages, 114
      - overview, 114
      - spleen role, 114–115
      - T cells, 114
    - ultrasound activation and kidney protection, 115–116
    - vagus nerve stimulation activation and kidney protection, 117
  - overview, 113–114
  - pharmacological therapy, 113
  - vagus nerve stimulation
    - optogenetics
      - C1 neuron stimulation, 119–120
      - devices, 118–119
    - overview, 117–118
- AF. *See* Atrial fibrillation
- AKI. *See* Acute kidney injury
- ALS. *See* Amyotrophic lateral sclerosis
- Amyloid fibrils
  - nicotinic acetylcholine receptor binding, 125, 135–137
  - small heat shock protein amyloid fibrils
    - endocytosis and migration to secondary lymph organs, 131
    - formation for therapeutic activity, 129–131
    - gene expression modulation, 134–135
    - knockout mouse studies, 131–134
- Amyotrophic lateral sclerosis (ALS), 279, 283–284, 306
- Aptasensor, electrophotonic diagnostics, 270
- Artificial pancreas. *See* Diabetes
- Atherosclerosis
  - inflammation resolution failure, 194
  - pathogenesis, 193–194
- Atrial fibrillation (AF), vagus nerve stimulation studies, 165–166

## B

- BCI. *See* Brain–computer interface
- Bioelectronic neural bypass, movement restoration
  - brain–computer interface, 305–307
  - chronic neural recordings, 311–312
  - feature selection and extraction, 312

- muscle contraction level control, 309–311
- neural decoding algorithms, 312–313
- prospects, 313–314
- rhythmic movement decoding, 307–309
- Bipolar electrode (BPE)
  - closed bipolar electrodes
    - molecular biomarker detection
      - assays, 272–273
      - prospects, 273–275
    - overview, 264–265
  - optical readout strategies, 265–266
  - principles, 264–265
- BPE. *See* Bipolar electrode
- Brain–computer interface (BCI), 305–307, 335

## C

- CAN. *See* Central autonomic network
- CAP. *See* Cholinergic anti-inflammatory pathway;  
Compound action potential
- Cardiac arrest, vagus nerve stimulation in resuscitation studies, 160–162
- Cardiac ischemia–reperfusion injury, small heat shock protein studies, 127
- Central autonomic network (CAN), brain–gut interactions, 225
- Central pattern generator (CPG), 307–308
- CGM. *See* Continuous glucose monitoring
- Cholinergic anti-inflammatory pathway (CAP)
  - acute kidney injury studies
    - ultrasound activation and kidney protection, 115–116
    - vagus nerve stimulation activation and kidney protection, 117
  - macrophages, 114
  - overview, 114
  - spleen role, 114–115
  - T cells, 114
  - ultrasound peripheral nerve stimulation, 145–146, 149
- Chronic intestinal pseudo-obstruction (CIPO)
  - electrical stimulation therapy
    - clinical trials, 255
    - dual-pulse stimulation, 250
    - electrode types, 251
    - inferential current stimulation, 250–251
    - multichannel stimulation, 250
  - parameters
    - amplitude/intensity, 249
    - duty cycle, 249
    - frequency, 249

## Index

- Chronic intestinal pseudo-obstruction (CIPO) (*Continued*)  
    pulse-width, 249–250  
    waveform, 249  
    synchronized stimulation, 250  
    targets, 248–249  
    overview, 255
- CIPO. *See* Chronic intestinal pseudo-obstruction
- CLN. *See* Closed-loop neuromodulation
- Closed bipolar electrode. *See* Bipolar electrode
- Closed-loop neuromodulation (CLN)  
    Components  
        acquisition system, 99  
        output device, 101  
        processing unit, 99–101  
        sensors, 97–99  
    conditions for use, 96–97  
    cortical stimulation for neuroplasticity induction,  
        101–103  
    hemodynamic function control with closed-loop  
        vagus nerve stimulation, 104  
    Parkinson's disease treatment, 103  
    prospects, 104–106  
    rationale  
        adaptive neuromodulation, 95–96  
        responsiveness, 94–95
- Coagulopathy, vagus nerve stimulation studies, 168
- Compound action potential (CAP), vagus nerve, 80–85
- Constipation  
    electrical stimulation therapy  
        colonic electrical stimulation, 256  
        dual-pulse stimulation, 250  
        electroacupuncture, 256–257  
        electrode types, 251  
        inferential current stimulation, 250–251  
        multichannel stimulation, 250  
    parameters  
        amplitude/intensity, 249  
        duty cycle, 249  
        frequency, 249  
        pulse-width, 249–250  
        waveform, 249  
    sacral nerve stimulation, 256  
    slow transit constipation, 256  
    synchronized stimulation, 250  
    targets, 248–249  
    tibial nerve stimulation, 256  
    transcutaneous electrical stimulation, 257  
    overview, 255–256
- Continuous glucose monitoring (CGM), 323–324
- Continuous subcutaneous insulin infusion (CSII), 321
- CPG. *See* Central pattern generator
- CRISPR, optogenetics, 48–50, 54
- CSII. *See* Continuous subcutaneous insulin infusion
- D**
- DBS. *See* Deep brain stimulation
- Deep brain stimulation (DBS)  
    ethics, 335–336
- Parkinson's disease closed-loop neuromodulation,  
    103
- Depression, enteric nervous system modulation for  
    treatment, 239
- Designer receptors exclusively activated by designer  
    drugs (DREADDs), 30–31
- Diabetes  
    artificial pancreas  
        historical perspective, 324  
        inpatient studies, 324  
        outpatient non-mobile units, 325  
        prospects, 327–328  
        system integration, 324–325  
        wearable units, 325–327  
    economic impact, 318  
    enteric nervous system modulation, 239  
    glucose monitoring and risk analysis, 321, 323–324  
    glucose-insulin control network, 318–320  
    hepatic ultrasound effects in animal models,  
        149–151  
    insulin therapies, 320–321  
    optogenetics devices, 46–47, 51–53  
    overview, 317–318  
    timeline of technology development, 322
- Disuse atrophy, 285
- DMD. *See* Duchenne muscular dystrophy
- DREADDs. *See* Designer receptors exclusively activated by  
    designer drugs
- Duchenne muscular dystrophy (DMD), 279, 283–285
- E**
- EAE. *See* Experimental autoimmune encephalitis
- EIG. *See* Electrical impedance myography
- EIT. *See* Electrical impedance tomography
- Electrical impedance myography (EIG)  
    amyotrophic lateral sclerosis, 283–284  
    applications, 282–283  
    diagnostics, 283  
    disuse atrophy, 285  
    Duchenne muscular dystrophy, 283–285  
    electrodes, 282  
    facioscapulohumeral muscular dystrophy, 285  
    muscle injury, 285–286  
    myotonic dystrophy, 285  
    needle impedance electromyography, 286–287  
    principles, 281–282  
    prospects, 287  
    sarcopenia, 285  
    spinal muscular atrophy, 283  
    virtual muscle biopsy, 286
- Electrical impedance tomography (EIT), muscle impedance  
    imaging, 286
- Electroacupuncture, constipation, 256–257
- Electrochemical zero-mode waveguide (E-ZMW), 267
- Electromagnetic devices  
    cell activity control, 63  
    clinical prospects, 71–73  
    genetically encoded particles, 68–71

- magnetic nanoparticles
  - aggregation to activate cell signaling, 66
  - mechanical stimulation, 63–66
  - thermal effects, 66–68
- Electromyography (EMG)
  - needle impedance electromyography, 286–287
  - overview, 280
- EMG. *See* Electromyography
- ENS. *See* Enteric nervous system
- Enteric nervous system (ENS)
  - indications for modulation
    - functional gastrointestinal disorder, 238–239
    - metabolic disorders, 239
    - psychiatric and mood disorders, 239–240
  - overview, 237–238
  - prospects for study
    - connectome unraveling, 242
    - ingestible devices, 243
    - moving target interfaces, 242–243
  - targets for modulation
    - direct organ stimulation, 240–242
    - extrinsic nervous system, 240
    - intrinsic nervous system, 240
- Epilepsy
  - overview, 176
  - treatment, 176–177
  - vagus nerve stimulation
    - animal studies, 177
    - clinical trials, 177–179
  - parameters
    - amplitude, 179–180
    - closed-loop stimulation, 180–181
    - duty cycle, 180
    - frequency, 180
    - pulse width, 179–180
  - prospects, 181
- Ethics, bioelectronic medicine
  - academic–industry relationships, 339–341
  - deep brain stimulation for Parkinson’s disease, 336
  - informed consent, 334–335
  - innovation, 337–339
  - intellectual property, 341
  - research ethics, 336–337
  - theories, 333–334
- Experimental autoimmune encephalitis (EAE)
  - nicotine therapy, 135–136
  - small heat shock protein studies
    - amyloid fibril formation for therapeutic activity, 129–131
    - history of study, 126–127
    - knockout mouse studies, 131–134
- E-ZMW. *See* Electrochemical zero-mode waveguide
- F**
- Facioscapulohumeral muscular dystrophy (FSHD), 283, 285
- FD. *See* Functional dyspepsia
- FSHD. *See* Facioscapulohumeral muscular dystrophy
- Functional dyspepsia (FD)
  - electrical stimulation therapy
    - clinical trials, 253–254
    - dual-pulse stimulation, 250
    - electrode types, 251
    - inferential current stimulation, 250–251
    - multichannel stimulation, 250
  - parameters
    - amplitude/intensity, 249
    - duty cycle, 249
    - frequency, 249
    - pulse-width, 249–250
    - waveform, 249
  - synchronized stimulation, 250
  - targets, 248–249
  - enteric nervous system modulation, 238
- G**
- Gastroesophageal reflux disease (GERD)
  - electrical stimulation therapy
    - clinical trials, 252–253
    - dual-pulse stimulation, 250
    - electrode types, 251
    - inferential current stimulation, 250–251
    - multichannel stimulation, 250
  - parameters
    - amplitude/intensity, 249
    - duty cycle, 249
    - frequency, 249
    - pulse-width, 249–250
    - waveform, 249
  - synchronized stimulation, 250
  - targets, 248–249, 252
  - overview, 252
- Gastrointestinal motility disorders. *See specific diseases*
- electrical stimulation targets, 248–249
- physiology, 248
- Gastroparesis
  - electrical stimulation therapy
    - dual-pulse stimulation, 250, 253
    - electrode types, 251
    - gastric slow wave alteration, 253
    - inferential current stimulation, 250–251
    - multichannel stimulation, 250
    - nausea and vomiting treatment, 253
  - parameters
    - amplitude/intensity, 249
    - duty cycle, 249
    - frequency, 249
    - pulse-width, 249–250
    - waveform, 249
  - spinal cord stimulation, 253
  - synchronized stimulation, 250
  - targets, 248–249
  - vagus nerve stimulation, 230–231
- GERD. *See* Gastroesophageal reflux disease
- GTS-21, 117

## Index

### H

- Heart failure (HF)
  - overview, 181–182
  - vagus nerve stimulation
    - animal studies, 162–163, 182–184
    - clinical trials, 184–186
    - prospects, 186
- Heart rate variability (HRV)
  - inflammatory bowel disease, 223
  - inflammatory reflex biomarker, 208
  - irritable bowel syndrome, 223
- Heat shock proteins. *See* Small heat shock proteins
- Heme oxygenase-1 (HO-1), 117
- Hemorrhagic shock, vagus nerve stimulation
  - studies, 168
- HF. *See* Heart failure
- HO-1. *See* Heme oxygenase-1
- HRV. *See* Heart rate variability
- Hypertension, vagus nerve stimulation studies, 168–169

### I

- IBD. *See* Inflammatory bowel disease
- IBS. *See* Irritable bowel syndrome
- ICG. *See* Impedance cardiography
- Impedance cardiography (ICG), 281
- Inflammation. *See also* Cholinergic anti-inflammatory pathway; Inflammatory reflex
  - neural control
    - B-cell function, 197–198
    - inflammatory reflex, 194–197
    - neural circuits, 197
    - resolution of inflammation, 198
    - therapeutic targeting, 198–199
  - neuroimmune interactions in acute kidney injury, 113–114
  - overview of response, 190–191
  - resolution
    - failure in inflammatory disease, 194
    - specialized pro-resolving mediators, 191–192
  - ultrasound peripheral nerve stimulation. *See* Ultrasound
- Inflammatory bowel disease (IBD)
  - brain–gut interaction defects, 227
  - economic impact, 222
  - inflammation resolution failure, 194
  - pathogenesis, 192–193
  - treatment, 189–190
  - vagus nerve stimulation, 5, 8–9, 198–199, 227–229
- Inflammatory reflex
  - biomarkers of activation, 207–208
  - brain signaling, 7
  - overview, 194–197, 205–207
  - vagus nerve role, 3–6
  - vagus nerve stimulation
    - clinical trials, 215–216
    - electrode architecture, 211–213
    - microstimulator development, 213–215

### parameters

- duty cycle, 211
  - output current, 208–210
  - pulse width, 210
  - stimulation location, 211–213
- Irritable bowel syndrome (IBS)
  - brain–gut interaction defects, 227
  - enteric nervous system modulation, 229, 238

### K

- Kidney injury. *See* Acute kidney injury

### L

- Lateral flow assay (LFA), point-of-care devices, 269
- LFA. *See* Lateral flow assay
- Localized surface plasmon resonance (LSPR)
  - aptasensors, 270
  - construction, 266
  - principles, 266
  - selectivity, 266–267
  - siderophore-based devices, 271–272
- LSPR. *See* Localized surface plasmon resonance

### M

- Magnetic nanoparticles. *See* Electromagnetic devices; Magnetolectric nanoparticle
- Magnetic resonance imaging (MRI), magnetolectric nanoparticles, 292–293, 300–301
- Magnetolectric nanoparticle (MENP)
  - imaging, 300–301
  - prospects, 301–302
  - single-neuron stimulation, 296–298
  - targeted drug delivery
    - blood–brain barrier release, 298
    - high-specificity intracellular targeted delivery, 298–300
  - traditional magnetic nanoparticle distinction, 293–296
- MENP. *See* Magnetolectric nanoparticle
- MI. *See* Myocardial infarction
- MRI. *See* Magnetic resonance imaging
- Myocardial infarction (MI), vagus nerve stimulation studies, 163–165
- Myotonic dystrophy, 285

### N

- NEMOS device, 231
- Neurochip BCI, 101
- NF- $\kappa$ B. *See* Nuclear factor  $\kappa$ B
- Nicotine, experimental autoimmune encephalitis treatment, 135–136
- Nicotinic acetylcholine receptor
  - amyloid fibril binding, 125, 135–137
  - inflammatory reflex, 195
- Nuclear factor  $\kappa$ B (NF- $\kappa$ B), 3, 5, 126–127

- O**
- Obesity
- electrical stimulation therapy
    - clinical trials, 254–255
    - dual-pulse stimulation, 250
    - electrode types, 251
    - inferential current stimulation, 250–251
    - multichannel stimulation, 250
    - parameters
      - amplitude/intensity, 249
      - duty cycle, 249
      - frequency, 249
      - pulse-width, 249–250
      - waveform, 249
    - synchronized stimulation, 250
    - targets, 248–249
    - vagus nerve stimulation, 230
  - enteric nervous system modulation, 239
  - overview, 254
- Optogenetics
- devices
    - cardiovascular disease, 44–46
    - diabetes, 46–47
    - gene activation, 50
    - gene editing, 48–50
    - mind-controlled transgene expression, 51
    - oncotherapy, 43–44
    - prospects, 53–54
    - smartphone device for diabetes, 51–53
  - overview, 19–22, 37–38, 61–62
  - peripheral nervous system control
    - awake animal studies, 29–30
    - breathing, 25–27
    - divergent vagal neuron populations, 23–25
    - gastrointestinal function, 27–29
    - overview, 19–22
  - prospects, 30–31
  - receptors, 38–43
  - vagus nerve stimulation and acute kidney injury
    - protection
      - C1 neuron stimulation, 119–120
    - devices, 118–119
- P**
- Parkinson's disease (PD), closed-loop neuromodulation, 103
- Pathogen, whole-cell detection with electrophotonic assays, 269–270
- PD. *See* Parkinson's disease
- Peripheral nervous system (PNS). *See also* Vagus nerve
- dysregulation in disease, 18
  - neurotransmitters and neuropeptides, 19
  - optogenetic control
    - awake animal studies, 29–30
    - breathing, 25–27
    - divergent vagal neuron populations, 23–25
    - gastrointestinal function, 27–29
    - overview, 19–22
    - overview, 17–19
  - PNS. *See* Peripheral nervous system
  - Point-of-care devices, diagnostics, 268–269
  - Postoperative ileus, vagus nerve stimulation, 229–230
- R**
- RA. *See* Rheumatoid arthritis
- Retinal ischemia, small heat shock protein studies, 127
- RF BION, 213–214
- Rheumatoid arthritis (RA)
  - inflammation resolution failure, 194
  - pathogenesis, 193
  - treatment, 189–190
  - vagus nerve stimulation, 199
- S**
- Sacral nerve, stimulation for constipation, 256
- Sarcopenia, 285
- SCI. *See* Spinal cord injury
- Shock. *See* Hemorrhagic shock
- Siderophore, electrophotonic diagnostics, 270–272
- Sjögren's syndrome, vagus nerve stimulation, 10
- SMA. *See* Spinal muscular atrophy
- Small heat shock proteins
  - amyloid fibrils
    - endocytosis and migration to secondary lymph organs, 131
    - formation for therapeutic activity, 129–131
    - gene expression modulation, 134–135
    - knockout mouse studies, 131–134
  - experimental autoimmune encephalitis
    - amyloid fibril formation for therapeutic activity, 129–131
    - history of study, 126–127
    - knockout mouse studies, 131–134
  - receptors, 135–137
  - structure–activity relationships, 128–129
  - therapeutic studies in animal models
    - cardiac ischemia–reperfusion injury, 127
    - retinal ischemia, 127
    - stroke, 127–128- Spinal cord injury (SCI), bioelectronic neural bypass, 306
- Spinal muscular atrophy (SMA), 283
- Stroke
  - bioelectronic neural bypass, 306
  - small heat shock protein studies, 127–128
  - vagus nerve stimulation studies, 166–167
- Support vector regression (SVR), 310
- Surface plasmon resonance. *See* Localized surface plasmon resonance
- SVR. *See* Support vector regression

**T**

TENS. *See* Transcutaneous electrical nerve stimulation

Tibial nerve, stimulation for constipation, 256

TMS. *See* Transcranial magnetic stimulation

## Index

- Transcranial magnetic stimulation (TMS), 63, 72, 335  
Transcutaneous electrical nerve stimulation (TENS),  
143, 257
- TREK-1, 64  
TRPV1, 65, 67, 69–71, 84  
TRPV4, 65, 69–71
- U**
- Ultrasound  
cholinergic anti-inflammatory pathway activation and  
kidney protection, 115–116  
peripheral nerve stimulation  
cholinergic anti-inflammatory pathway,  
145–146, 149  
hepatic stimulation in metabolism and diabetes  
models, 149  
hepatic ultrasound comparison with implant-based  
stimulation, 151–152  
lipopolysaccharide-induced inflammation  
model, 145  
overview, 143–147  
prospects, 152–153  
splenic stimulation and inflammation, 147–149
- V**
- Vagus nerve (VN)  
afferents in neuroimmune dialogue, 6  
anatomy, 3, 23–25  
inflammatory reflex role, 3–6  
optogenetic control  
awake animal studies, 29–30  
breathing, 25–27  
divergent vagal neuron populations, 23–25  
gastrointestinal function, 27–29  
overview, 19–22  
signal interpretation  
inflammation-related signals, 79–84  
metabolic state-related signals, 84–85  
overview, 77–79  
prospects for study, 88–89  
respiration and blood pressure biomarkers, 86–88  
sympathovagal balance, 222–223
- Vagus nerve stimulation (VNS)  
acute kidney injury protection  
cholinergic anti-inflammatory pathway  
activation, 117–118  
optogenetics  
C1 neuron stimulation, 119–120  
devices, 118–119  
animal models of inflammatory diseases, 7–9  
anti-inflammatory mechanisms, 226–227  
atrial fibrillation studies, 165–166  
cardiac arrest resuscitation studies, 160–162  
coagulopathy studies, 168  
devices, 116–117  
gastroparesis, 230–231  
heart failure studies, 162–163  
hemodynamic function control with closed-loop  
nerve stimulation, 104  
hemorrhagic shock studies, 168  
hepatic ultrasound comparison with implant-based  
stimulation, 151–152  
historical perspective, 1–3, 18, 157–160  
hypertension studies, 168–169  
inflammatory bowel disease, 5, 8–9, 198–199, 227–229  
inflammatory reflex induction  
clinical trials, 215–216  
electrode architecture, 211–213  
microstimulator development, 213–215  
parameters  
duty cycle, 211  
output current, 208–210  
pulse width, 210  
stimulation location, 211–213  
invasive versus noninvasive, 231  
irritable bowel syndrome, 229  
myocardial infarction studies, 163–165  
neuromodulation, 141–143  
obesity, 230  
postoperative ileus, 229–230  
prospects  
applications, 10–11  
gastrointestinal disorder treatment, 231–232  
side effects, 169–170  
stroke studies, 166–167  
technical challenges, 143  
therapeutic applications, 9–10  
tumor necrosis factor response, 196  
ultrasound. *See* Ultrasound  
rheumatoid arthritis, 199  
inflammatory bowel disease, 5, 8–9, 198–199
- VN. *See* Vagus nerve  
VNS. *See* Vagus nerve stimulation